Audrey Mansuet-Lupo1, Antonio Bobbio2, Hélène Blons3, Etienne Becht4, Hanane Ouakrim5, Audrey Didelot6, Marie-Christine Charpentier7, Serge Bain7, Béatrice Marmey8, Patricia Bonjour8, Jérôme Biton8, Isabelle Cremer8, Marie-Caroline Dieu-Nosjean8, Catherine Sautès-Fridman8, Jean-François Régnard9, Pierre Laurent-Puig3, Marco Alifano9, Diane Damotte10. 1. INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Université Denis Diderot-Paris 7, Paris, France; Service de Pathologie, Paris, France. 2. Hôpitaux Universitaire Paris Centre, AP-HP, Service de Chirurgie Thoracique, Paris, France. 3. Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Hôpitaux Universitaire Paris Centre, AP-HP, Service de Chirurgie Thoracique, Paris, France; Hôpitaux Universitaire Paris Centre, AP-HP, Service de Biochimie, Paris, France; Hôpital Européen Georges Pompidou, AP-HP; and UMR-S775, Paris, France; INSERM, Faculté de médecine des Saints Pères, Paris, France. 4. INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Université Denis Diderot-Paris 7, Paris, France. 5. INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France. 6. Hôpital Européen Georges Pompidou, AP-HP; and UMR-S775, Paris, France; INSERM, Faculté de médecine des Saints Pères, Paris, France. 7. Service de Pathologie, Paris, France. 8. INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France. 9. Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Hôpitaux Universitaire Paris Centre, AP-HP, Service de Chirurgie Thoracique, Paris, France. 10. INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Université Denis Diderot-Paris 7, Paris, France; Service de Pathologie, Paris, France. Electronic address: diane.damotte@htd.aphp.fr.
Abstract
BACKGROUND: Histologic classification of lung adenocarcinoma subtype has a prognostic value in most studies. However, lung adenocarcinoma characteristics differ across countries. Here, we aimed at validating the prognostic value of this classification in a large French series of lung adenocarcinoma. METHODS: We reviewed 407 consecutive lung adenocarcinomas operated on between 2001 and 2005 and reclassified them according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and subsequently graded them into low, intermediate, and high grade. We analyzed the relevance of this classification according to clinical, pathologic, and molecular analysis. RESULTS: Patients (median age, 61 years; 288 men) underwent lobectomy (n = 378) or pneumonectomy (n = 29). Patients' overall survival at 5 and 10 years was 53.2% and 32.6%, respectively. Union for International Cancer Control stage distribution was 189 stage I, 104 stage II, 107 stage III, and seven stage IV. Low-grade tumor was found in one patient, intermediate grade in 275 patients, and high grade in 131 patients. KRAS and EGFR mutations were detected in 34% and 9.6%, respectively. Histologic grade was significantly correlated with extent of resection (P = .01), thyroid transcriptional factor-1 expression (P = .00000001), vascular emboli (P = .03), and EGFR mutations (P = .01). Mucinous adenocarcinomas were associated with KRAS mutations (P = .003). At univariate analysis, age, extent of resection, histologic grade, pleural invasion, vascular emboli, pathologic T and N, and stage were predictive of survival. At multivariate analysis, age (P = .0001), histologic grade (P = .03), and stage (P = .000003) were independent prognostic factors. CONCLUSIONS: IASLC/ATS/ERS classification of lung adenocarcinomas predicts survival in French population. Histologic grade correlates with clinical, pathologic and molecular parameters suggesting different oncogenic pathways.
BACKGROUND: Histologic classification of lung adenocarcinoma subtype has a prognostic value in most studies. However, lung adenocarcinoma characteristics differ across countries. Here, we aimed at validating the prognostic value of this classification in a large French series of lung adenocarcinoma. METHODS: We reviewed 407 consecutive lung adenocarcinomas operated on between 2001 and 2005 and reclassified them according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and subsequently graded them into low, intermediate, and high grade. We analyzed the relevance of this classification according to clinical, pathologic, and molecular analysis. RESULTS:Patients (median age, 61 years; 288 men) underwent lobectomy (n = 378) or pneumonectomy (n = 29). Patients' overall survival at 5 and 10 years was 53.2% and 32.6%, respectively. Union for International Cancer Control stage distribution was 189 stage I, 104 stage II, 107 stage III, and seven stage IV. Low-grade tumor was found in one patient, intermediate grade in 275 patients, and high grade in 131 patients. KRAS and EGFR mutations were detected in 34% and 9.6%, respectively. Histologic grade was significantly correlated with extent of resection (P = .01), thyroid transcriptional factor-1 expression (P = .00000001), vascular emboli (P = .03), and EGFR mutations (P = .01). Mucinous adenocarcinomas were associated with KRAS mutations (P = .003). At univariate analysis, age, extent of resection, histologic grade, pleural invasion, vascular emboli, pathologic T and N, and stage were predictive of survival. At multivariate analysis, age (P = .0001), histologic grade (P = .03), and stage (P = .000003) were independent prognostic factors. CONCLUSIONS: IASLC/ATS/ERS classification of lung adenocarcinomas predicts survival in French population. Histologic grade correlates with clinical, pathologic and molecular parameters suggesting different oncogenic pathways.
Authors: Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Takashi Eguchi; Kyuichi Kadota; Bernard J Park; William D Travis; David R Jones; Prasad S Adusumilli Journal: Semin Thorac Cardiovasc Surg Date: 2014-09-16
Authors: Alison K Bauer; Misha Umer; Vanessa L Richardson; Amber M Cumpian; Anna Q Harder; Nasim Khosravi; Zoulikha Azzegagh; Naoko M Hara; Camille Ehre; Maedeh Mohebnasab; Mauricio S Caetano; Daniel T Merrick; Adrie van Bokhoven; Ignacio I Wistuba; Humam Kadara; Burton F Dickey; Kalpana Velmurugan; Patrick R Mann; Xian Lu; Anna E Barón; Christopher M Evans; Seyed Javad Moghaddam Journal: JCI Insight Date: 2018-08-09